Ipsen (FR:IPN) has released an update.
Ipsen’s new drug Iqirvo® has received FDA approval for the treatment of primary biliary cholangitis (PBC), marking the first PPAR class therapeutic and the first new drug for PBC in a decade. Granted via an accelerated procedure based on positive Phase III trial data, Iqirvo® offers hope for approximately 100,000 U.S. patients, potentially preventing liver failure when other treatments are inadequate. The company strengthens its portfolio in rare liver diseases with this approval, while further studies are underway to confirm long-term benefits.
For further insights into FR:IPN stock, check out TipRanks’ Stock Analysis page.
